See more : SRM Entertainment, Inc. (SRM) Income Statement Analysis – Financial Results
Complete financial analysis of Sichuan Goldstone Asia Pharmaceutical Inc. (300434.SZ) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Sichuan Goldstone Asia Pharmaceutical Inc., a leading company in the Industrial – Distribution industry within the Industrials sector.
- Landmark Infrastructure Partners LP (LMRKN) Income Statement Analysis – Financial Results
- AbbVie Inc. (4AB.DU) Income Statement Analysis – Financial Results
- Southern ITS International, Inc. (SITS) Income Statement Analysis – Financial Results
- Toshiba Corporation (6502.T) Income Statement Analysis – Financial Results
- SMN Corporation (6185.T) Income Statement Analysis – Financial Results
Sichuan Goldstone Asia Pharmaceutical Inc. (300434.SZ)
About Sichuan Goldstone Asia Pharmaceutical Inc.
Sichuan Goldstone Asia Pharmaceutical Inc. engages in the research, development, manufacture, and sale of medicines and health products in China and internationally. The company offers various pharmaceutical preparations and APIs; Chinese and western pharmaceutical preparations and raw materials; and tablets, capsules, dietary supplements, vitamin products, OTC products, and prescription drugs. It also trades in various pharmaceutical products, such as Chinese herbal medicine materials, Chinese patent medicines, Chinese herbal pieces, chemical raw materials, pharmaceutical preparations, antibiotic preparations, biochemical drugs, dietary supplements, and toxic drugs for medical use, medical devices, etc.; and sells adult drug products under the Quike brand and children's general medicine products under the Mini-Quike brand name. In addition, the company researches, develops, manufactures, and sells plastic composite pipe and vacuum coating machines. Further, it offers reinforced pipe equipment, such as steel reinforced corrugated pipes, reinforced composite polyethylene pipes, fiberglass reinforced RTP pipes, steel reinforced large diameter pipes, steel reinforced corrugated pipe socket and spigot making machines, abrasion resistant industries pipes, extrusion pipe fittings, and perforated steel reinforced polyethylene composite pipes. Additionally, the company provides vacuum coating equipment, including low-emissivity glass coating lines, reflect glass magnetron sputtering coating lines, magnetron sputtering mirror coating production lines, vacuum sputter systems for automotive car mirrors, ITO/TCO glass coating machines, sputtering metallization machines, optical lens coating machines, roll web metallization machines, and air-to-air solar absorption strip sputtering production line; and smart parking equipment. Sichuan Goldstone Asia Pharmaceutical Inc. was founded in 2001 and is based in Chengdu, China.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.21B | 1.24B | 1.05B | 777.30M | 1.01B | 970.72M | 704.01M | 162.41M | 117.11M | 172.83M | 238.59M | 264.18M | 231.34M |
| Cost of Revenue | 467.17M | 480.50M | 455.72M | 358.41M | 357.44M | 330.71M | 253.42M | 106.17M | 71.05M | 104.57M | 149.76M | 159.50M | 134.82M |
| Gross Profit | 742.03M | 762.11M | 597.78M | 418.89M | 648.17M | 640.00M | 450.59M | 56.24M | 46.07M | 68.26M | 88.83M | 104.68M | 96.52M |
| Gross Profit Ratio | 61.37% | 61.33% | 56.74% | 53.89% | 64.46% | 65.93% | 64.00% | 34.63% | 39.34% | 39.49% | 37.23% | 39.63% | 41.72% |
| Research & Development | 50.01M | 39.18M | 37.45M | 27.84M | 28.54M | 27.92M | 21.09M | 10.38M | 8.82M | 9.72M | 12.08M | 12.99M | 0.00 |
| General & Administrative | 39.11M | 46.74M | 33.39M | 37.37M | 33.27M | 30.69M | 26.44M | 5.32M | 4.02M | 2.72M | 1.89M | 3.23M | 23.05M |
| Selling & Marketing | 150.60M | 257.84M | 267.92M | 222.77M | 268.77M | 267.31M | 155.98M | 10.42M | 7.79M | 8.84M | 10.21M | 11.30M | 10.50M |
| SG&A | 428.95M | 304.57M | 301.31M | 260.14M | 302.04M | 298.00M | 182.42M | 15.74M | 11.81M | 11.57M | 12.09M | 14.53M | 33.55M |
| Other Expenses | 85.13M | -1.43M | 4.55M | 2.85M | -512.99K | -445.44K | 3.01M | 5.11M | 6.06M | 228.41K | 3.34M | 330.00K | 558.01K |
| Operating Expenses | 564.09M | 469.38M | 467.93M | 412.97M | 466.10M | 450.23M | 296.25M | 35.83M | 28.87M | 31.84M | 35.53M | 38.33M | 35.03M |
| Cost & Expenses | 1.03B | 949.88M | 923.65M | 771.38M | 823.53M | 780.95M | 549.67M | 142.00M | 99.91M | 136.42M | 185.29M | 197.82M | 169.84M |
| Interest Income | 12.09M | 2.74M | 2.97M | 4.32M | 4.26M | 2.19M | 1.26M | 381.28K | 1.66M | 1.00M | 650.76K | 328.19K | -0.07 |
| Interest Expense | 671.75K | 460.38K | 15.47K | 170.26K | 947.46K | 2.45M | 10.34M | 594.30K | 1.83M | 35.92K | 27.10K | 270.33K | 99.73K |
| Depreciation & Amortization | 94.41M | 94.68M | 88.36M | 88.38M | 86.17M | 84.32M | 50.03M | 3.26M | 2.90M | 2.71M | 2.32M | 1.92M | -2.17M |
| EBITDA | 272.10M | 382.32M | 180.67M | -572.48M | 242.70M | 275.80M | 211.40M | 32.39M | 29.76M | 39.60M | 59.29M | 68.53M | 60.37M |
| EBITDA Ratio | 22.50% | 30.15% | 20.36% | 12.41% | 26.61% | 28.25% | 29.52% | 15.25% | 17.54% | 23.61% | 24.91% | 26.08% | 26.09% |
| Operating Income | 177.94M | 291.97M | 88.98M | -667.94M | 160.57M | 189.28M | 148.24M | 23.98M | 20.77M | 36.66M | 53.45M | 65.80M | 62.54M |
| Operating Income Ratio | 14.72% | 23.50% | 8.45% | -85.93% | 15.97% | 19.50% | 21.06% | 14.77% | 17.74% | 21.21% | 22.40% | 24.91% | 27.03% |
| Total Other Income/Expenses | -921.84K | -1.43M | 4.55M | 2.85M | -512.98K | -445.44K | -238.93K | 5.11M | 6.06M | 228.41K | 3.33M | 324.82K | 550.06K |
| Income Before Tax | 177.02M | 290.54M | 93.54M | -665.09M | 160.06M | 188.83M | 151.24M | 29.09M | 26.83M | 36.89M | 56.79M | 66.12M | 63.09M |
| Income Before Tax Ratio | 14.64% | 23.38% | 8.88% | -85.56% | 15.92% | 19.45% | 21.48% | 17.91% | 22.91% | 21.34% | 23.80% | 25.03% | 27.27% |
| Income Tax Expense | 56.31M | 77.49M | 27.43M | 19.38M | 34.19M | 35.52M | 34.52M | 3.93M | 3.45M | 4.78M | 7.89M | 9.26M | 9.12M |
| Net Income | 126.20M | 218.79M | 66.48M | -687.66M | 120.33M | 149.15M | 115.87M | 25.53M | 23.38M | 32.11M | 48.90M | 56.86M | 53.97M |
| Net Income Ratio | 10.44% | 17.61% | 6.31% | -88.47% | 11.97% | 15.37% | 16.46% | 15.72% | 19.96% | 18.58% | 20.50% | 21.52% | 23.33% |
| EPS | 0.31 | 0.54 | 0.17 | -1.71 | 0.30 | 0.37 | 0.37 | 0.11 | 0.10 | 0.18 | 0.27 | 0.31 | 0.29 |
| EPS Diluted | 0.31 | 0.54 | 0.17 | -1.71 | 0.30 | 0.37 | 0.37 | 0.11 | 0.10 | 0.18 | 0.27 | 0.31 | 0.29 |
| Weighted Avg Shares Out | 407.10M | 401.74M | 401.74M | 401.74M | 401.74M | 401.74M | 313.81M | 241.83M | 224.45M | 183.46M | 183.38M | 184.41M | 183.30M |
| Weighted Avg Shares Out (Dil) | 407.10M | 401.74M | 401.74M | 401.74M | 401.74M | 403.12M | 313.81M | 241.83M | 224.45M | 183.46M | 183.38M | 184.41M | 183.30M |
Source: https://incomestatements.info
Category: Stock Reports